Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Transplant Surgery
  •  Colon and Rectal Surgery
  •  Pediatric Surgery
  •  Orthopaedic Surgery
  •  Gastroenterological Surgery
  •  Bariatric Surgery
  •  Surgical Oncology
  •  Emergency Surgery

Abstract

Citation: Clin Surg. 2020;5(1):2899.Research Article | Open Access

Efficacy and Safety of Pilocarpine Hydrochloride in the Treatment of Voiding Difficulty in Patients with Detrusor Underactivity

Kanya Kaga1, Tomohiko Kamasako1, Mayuko Kaga1, Miki Fuse1, Mitsuru Ishizuka2 and Tomonori Yamanishi1*

1Department of Urology, Continence Center, Dokkyo Medical University, Tochigi, Japan
2Department of Surgery, Continence Center, Dokkyo Medical University, Tochigi, Japan

*Correspondance to: Tomonori Yamanishi 

 PDF  Full Text DOI: 10.25107/2474-1647.2899

Abstract

Background and Objective: We previously examined the contractile effect of pilocarpine on pig and human isolated bladder smooth muscle. The present study exploratorily investigated the efficacy and safety of pilocarpine for the treatment of voiding difficulty due to detrusor underactivity. Methods: Patients with voiding symptoms, maximum urinary flow rate (Qmax) ≤ 10 mL/s, and Post-Void Residual urine volume (PVR) ≥ 50 mL, and diagnosed with detrusor underactivity in a pressure-flow study, were treated with pilocarpine (a dose of 5 mg 3 times daily) for 8 weeks. The primary endpoint was the change in Qmax vs. baseline. The secondary endpoints were changes in the International Prostate Symptom Score (IPSS; total IPSS, voiding symptoms including sensation of incomplete emptying), Quality of Life (QOL) score, and average urinary flow rate (Qave). Results: In uroflowmetry, significant changes were demonstrated (Qmax, 9.1 ± 4.6 to 12.9 ± 5.5 ml/s, P=0.0313; Qave, 6.1 ± 5.3 to 8.8 ± 6.3 ml/s, P=0.0039; voided volume, 158.8 ± 114.5 to 186.8 ± 110.0 ml, P=0.0273; and PVR, 222.7 ± 122.3 to 102.4 ± 92.9 ml, P=0.0020). IPSS total score and IPSS voiding symptom score were significantly decreased after the treatment (IPSS total score, 15.8 ± 9.4 to 12.1 ± 9.0 points, P=0.0039; voiding symptom subtotal score, 9.3 ± 6.1 to 7.3 ± 5.7 points, P=0.0469). Conclusion: Pilocarpine improved voiding symptoms scores and urinary flow rates, decreasing PVR. Pilocarpine appeared to be safe and effective for the treatment of detrusor underactivity in patients with voiding difficulty due to detrusor underactivity.

Keywords

Cite the article

Kaga K, Kamasako T, Kaga M, Fuse M, Ishizuka M, Yamanishi T. Efficacy and Safety of Pilocarpine Hydrochloride in the Treatment of Voiding Difficulty in Patients with Detrusor Underactivity. Clin Surg. 2020; 5: 2899..

Search Our Journal

Journal Indexed In

Articles in PubMed

Automated Sagittal Craniosynostosis Classification from CT Images Using Transfer Learning
 PubMed  PMC  PDF  Full Text
Monitoring an Ongoing Enhanced Recovery after Surgery (ERAS) Program: Adherence Improves Clinical Outcomes in a Comparison of Three Thousand Colorectal Cases
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Optimal Surgical Procedure for Ovarian Metastases from Colorectal Cancer based on a Retrospective Analysis
 Abstract  PDF  Full Text
Protein Identification and Haplotype Description of Homozygote Mutation Causing Congenital Plasminogen Deficiency
 Abstract  PDF  Full Text
View More...